MEDP Stock Analysis: Buy, Sell, or Hold?
MEDP - Medpace Holdings, Inc. Common Stock
$460.30
9.10 (2.02%)
▲
5d:
+0.74%
30d:
+1.89%
90d:
-18.9%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: Apr 22, 2026
22d
Smart Money Accumulation
MEDP is down 4.6% this week, but smart money is accumulating calls. Top strike: $490 2026-04-17 with 3 OI. Call ratio: 100% View Scanner →
Strength: 7.3/10
Get Alerted When MEDP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: MEDP appears deeply undervalued. Market expects -8.3% annual earnings decline despite 27% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: MEDP appears deeply undervalued. Market expects -8.3% annual earnings decline despite 27% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$677.72
Based on 7.2% avg growth
INTRINSIC VALUE TODAY
$420.81
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: MEDP is currently trading at $460.30, which is considered fair relative to its 30-day fair value range of $447.22 to $467.77. From a valuation perspective, the stock is trading at a discount (Forward PE: 23.5) compared to its historical average (30.5). Remarkably, the market is currently pricing in an annual earnings decline of 8.3% over the next few years. This pessimistic expectation contrasts with the company's recent 26.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, MEDP is in a strong downtrend. The price is currently testing key support at $446.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $496.75 (+10.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MEDP is in a strong downtrend. The price is currently testing key support at $446.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $496.75 (+10.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$447.22 -
$467.77
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
75.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($496.75)
Fair Price Analysis
30-Day Fair Range
$447.22 -
$467.77
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$27.22
(5.9%)
Support & Resistance Levels
Support Level
$446.89
Resistance Level
$475.80
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.54
Wall Street Target
$496.75
(+10.1%)
Revenue Growth (YoY)
32.0%
Earnings Growth (YoY)
26.9%
Profit Margin
17.8%
Valuation Discount vs History
-8.3% cheaper
PE vs Historical
23.5 vs 30.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.3%
(market-implied from PE analysis)
1-Year Target
$413.75
(-8%)
2-Year Target
$379.41
(-16%)
3-Year Target
$347.92
(-23%)
3-Yr Target (if PE normalizes)
(PE: 24→31)
$450.85
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.5, Growth: 10.4%)
$606.32
(+34%)
Base:
(SPY PE: 22.4, Growth: 10.4%)
$577.03
(+28%)
Bear:
(PE: 19.0, Growth: 10.4%)
$490.48
(+9%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (30x PE), but valuation improves significantly next year (24x PE) as earnings recover.
Trailing PE: 29.60 | Current EPS (TTM): $15.29
Bull Case
$624.07
(+37%)
Analyst growth 25.4%, PE expands to 32.6
Base Case
$567.34
(+24%)
Market implied 25.4%, PE stable at 29.6
Bear Case
$307.71
(-33%)
Severe decline -20.0%, PE contracts to 25.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 23.5 to 30.5
Stabilization Target:
$584.68
(+29.6%)
PE Expansion Potential:
+29.6%
Share & Embed Analysis
Last updated: March 30, 2026 4:25 PM ET
Data refreshes hourly during market hours. Next update: 5:25 PM
Data refreshes hourly during market hours. Next update: 5:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MEDP showing a specific setup today?
Insider Activity (6 Months)
2
Buys
18
Sells
Net
INSIDERS SELLING
Recent Transactions
David Taylor
BUY
2026-02-26
David Taylor
BUY
2026-01-29
David Taylor
SELL
2026-01-16
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$664 | 60 BUY |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$265 | 61 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$133 | 56 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 54 HOLD |
Advanced MEDP Option Strategies
Professional options setups generated by AI based on today's MEDP price and gamma walls.
